RenovoRx, Inc. (RNXT) stock
RNXTNasdaqSurgical & Medical Instruments & ApparatusFiscal year ends December 31
$1.12+0.08 (+7.69%)
Close on Nov 18, 2026Market cap $50.55MP/E –Yield –
RenovoRx free cash flow
Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.
RenovoRx's free cash flow for the twelve months ending Jun 30, 2026 was -$11.94M. For fiscal 2025 it was -$10.98M.
Annual free cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$10.98M | – |
| FY2024 | Dec 31, 2024 | -$9.14M | – |
Quarterly free cash flow
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$2.94M | – |
| Q1 FY2026 | Mar 31, 2026 | -$3.71M | – |
| Q4 FY2025 | Dec 31, 2025 | -$3.02M | – |
| Q3 FY2025 | Sep 30, 2025 | -$2.27M | – |
| Q2 FY2025 | Jun 30, 2025 | -$2.30M | – |
| Q1 FY2025 | Mar 31, 2025 | -$3.38M | – |
See a number that looks wrong?